(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/119040 A1

(51) International Patent Classification:
C12N 5/10 (2006.01) *A61P 7/06* (2006.01)
A61K 35/28 (2015.01) *A61K 48/00* (2006.01)

(21) International Application Number:
PCT/US2020/063854

(22) International Filing Date:
09 December 2020 (09.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/945,190 08 December 2019 (08.12.2019) US
63/115,518 18 November 2020 (18.11.2020) US

(71) Applicant: **EDITAS MEDICINE, INC.** [US/US]; 11 Hurley Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **GORI, Jennifer Leah**; 20 Spalding Street, Unit 1, Jamaica Plain, Massachusetts 02130 (US). **AUPEPIN DE LAMOTHE-DREUZY, Edouard**; 123 Pinckney Street, Boston, Massachusetts 02114 (US). **HEATH, Jack**; 1 Wildwood Street, Winchester, Massachusetts 01890 (US). **ZURIS, John Anthony**; 8 Manley Street, Unit 2, Boston, Massachusetts 02122 (US). **CHANG, KaiHsin**; 113 Wood End Lane, Medfield, Massachusetts 02052 (US).

(74) Agent: **PROCHNOW, Courtney**; PERKINS COIE LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MODIFIED CELLS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

FIG 1



(57) Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the *HBG1* and *HBG2* loci in cells and increasing expression of fetal hemoglobin.

WO 2021/119040 A1